It is generally known that cardiac complications are common in patients with severe respiratory disease such as pneumonia 1-4. Since the start of the outbreak, it is known that underlying cardiovascular diseases are a risk factor for severe COVID-19 development 5.
Just recently, the European Society of Cardiology published their ‘Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic’6. One of the key points from this guidance is that in patients with COVID-19, as in patients with other pneumonias, it is suggested to measure cardiac troponin T/I concentrations only if the diagnosis of Type 1 Myocardial Infarction is being considered on clinical grounds, or in new onset LV dysfunction. Independently from diagnosis, monitoring of cardiac troponin T/I may help for the purpose of prognostication.
In a meta-analysis of 4 studies, patients with severe COVID-19 had significantly higher cardiac high sensitivity troponin levels versus those with mild disease, with a mean Δ of 25 ng/L 7.
Based on the currently available literature, cardiac biomarkers may be useful in patients with CVD who develop COVID-19 for risk stratification and possible early and more aggressive interventions8